AAM Amicus Brief - Mylan vs. Allergan | Association for Accessible Medicines
AAM Statement - President Trump’s Blueprint to Lower Drug Prices

AAM Amicus Brief - Mylan vs. Allergan

Generic drug and biosimilar companies support innovation in medicine to benefit patients. Brand name drug companies who abuse the patent system harm patients. See our amicus brief opposing the rental of Native American tribal sovereign immunity by a brand name pharmaceutical company to extend its drug patent monopoly and keep prices high.

View Brief

Association for Accessible Medicines

202.249.7100

Sign-up for Updates

Receive relevant industry news, event information and the latest resources on biosimilars and generic medicines.

Stay Connected

For the latest updates, follow us on social media.